EosGene Therapeutics: Pioneering Gene Therapy for a Brighter Future
EosGene Tx is dedicated to address a significant healthcare challenge of diabetic retinopathy by harnessing the power of CRISPR-based gene therapy. With our ground-breaking liposome delivery technology, we're at the forefront of transforming treatment possibilities.
Our approach employs the revolutionary CRISPR editing tool to precisely target the disease-associated gene, paving the way for therapeutic breakthroughs. To ensure both effectiveness and safety of the therapy, we've developed an innovative liposome delivery technology that achieves the spatial-temporal release of CRISPR agents to the affected retinal cells.
Our objective is clear: to halt or even reverse the progression of diabetic retinopathy by correcting genetic mutations and dysfunctions at their source.
Guided by world-class scientists and business leaders, our team brings a wealth of experience and expertise in the dynamic realm of biotechnology.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Sydney, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.eosgene.com
- Keywords
- Nanoparticles, Liposomes, Gene Therapy, Clinical Trials, Safer, more efficient and affordable treatments, Genome Editing.
- HQ
- Sydney
Eosgene Therapeutics Questions
Eosgene Therapeutics's website is http://www.eosgene.com
Eosgene Therapeutics's LinkedIn profile is https://au.linkedin.com/company/eosgene
Eosgene Therapeutics has
1 employees.
View email and phone details for 1
employees at Eosgene Therapeutics.
Eosgene Therapeutics's industry is
Biotechnology Research
Eosgene Therapeutics's top competitors are
Orio Therapeutics,
Countercurrent Ai,
Contactile,
Ryoss,
Preview Health,
Merck Group,
Radiant Jelly,
Smart Crc,
Stemsight,
Ubiqut.
Eosgene Therapeutics's categories are Biotechnology Research
Eosgene Therapeutics's founding year is 2022
